Third Rock Ventures has led a series A round for Abata Therapeutics that also featured fellow existing investor ElevateBio.

Abata Therapeutics, a US-based cell therapy developer focused on autoimmune and inflammatory diseases, has launched with $95m in series A financing from investors including gene and cell therapy developer ElevateBio.

The round was led by healthcare-focused venture capital firm Third Rock Ventures and also featured Lightspeed Venture Partners, Invus, Samsara BioCapital and JDRF T1D Fund. It followed an undisclosed amount of seed capital supplied by Third Rock and ElevateBio at an unspecified date.

Founded in 2018, Abata is working on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn